IL190583A0 - Pth formulations and methods of use - Google Patents

Pth formulations and methods of use

Info

Publication number
IL190583A0
IL190583A0 IL190583A IL19058308A IL190583A0 IL 190583 A0 IL190583 A0 IL 190583A0 IL 190583 A IL190583 A IL 190583A IL 19058308 A IL19058308 A IL 19058308A IL 190583 A0 IL190583 A0 IL 190583A0
Authority
IL
Israel
Prior art keywords
methods
pth formulations
pth
formulations
Prior art date
Application number
IL190583A
Other languages
English (en)
Original Assignee
Mdrna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/246,450 external-priority patent/US20060052306A1/en
Priority claimed from US11/246,406 external-priority patent/US20060052305A1/en
Priority claimed from US11/347,551 external-priority patent/US20060127320A1/en
Priority claimed from US11/390,940 external-priority patent/US20060189533A1/en
Priority claimed from PCT/US2006/013377 external-priority patent/WO2007044069A2/en
Application filed by Mdrna Inc filed Critical Mdrna Inc
Publication of IL190583A0 publication Critical patent/IL190583A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL190583A 2005-10-06 2008-04-02 Pth formulations and methods of use IL190583A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/246,450 US20060052306A1 (en) 2004-05-10 2005-10-06 GRAS composition for enhanced mucosal delivery of parathyroid hormone
US11/246,406 US20060052305A1 (en) 2004-05-10 2005-10-06 Method of treating osteoporosis using intranasal parathyroid hormone
US11/347,551 US20060127320A1 (en) 2004-05-10 2006-02-03 Method of delivering parathyroid hormone to a human
US11/390,940 US20060189533A1 (en) 2004-05-10 2006-03-27 Stable pharmaceutical dosage forms of teriparatide
PCT/US2006/013377 WO2007044069A2 (en) 2005-10-06 2006-04-10 Pth formulations and methods of use

Publications (1)

Publication Number Publication Date
IL190583A0 true IL190583A0 (en) 2008-11-03

Family

ID=39595926

Family Applications (1)

Application Number Title Priority Date Filing Date
IL190583A IL190583A0 (en) 2005-10-06 2008-04-02 Pth formulations and methods of use

Country Status (4)

Country Link
JP (1) JP2009511472A (ja)
KR (1) KR20080059430A (ja)
CA (1) CA2625084A1 (ja)
IL (1) IL190583A0 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3685850A4 (en) * 2017-09-22 2021-06-16 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT PHARMACODYNAMIC PROPERTIES AND / OR STABILITY
CA3075977A1 (en) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
KR102163445B1 (ko) 2017-11-20 2020-10-07 주식회사 노브메타파마 Chp(사이클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
KR102115353B1 (ko) 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
CN114272511B (zh) * 2021-01-12 2023-08-01 广州新济药业科技有限公司 司美格鲁肽可溶性微针贴片及其制备方法

Also Published As

Publication number Publication date
JP2009511472A (ja) 2009-03-19
CA2625084A1 (en) 2007-04-19
KR20080059430A (ko) 2008-06-27

Similar Documents

Publication Publication Date Title
EP1909644A4 (en) INSERTION APPARATUS AND METHODS OF USE
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
ZA200709626B (en) Multicyclic compounds and methods of their use
EP1933884A4 (en) PICTURES AND METHOD FOR THEIR USE
EP1945137A4 (en) PARTLY COVERED STENT DEVICES AND APPLICATION METHODS
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL176958A0 (en) Compounds and methods of use
IL184735A0 (en) Pharmaceutical formulations and methods of use
HK1213814A1 (zh) 雙氯芬酸製劑和使用方法
SG10201504801VA (en) Azaindazole compounds and methods of use
EP1874731A4 (en) CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
ZA200710173B (en) Tygecycline and methods of preparing 9-nitrominocycline
EP1778210A4 (en) CONJUGATES OF FATTY ACID AND AMINO ACIDS AND METHODS OF USE
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1899198A4 (en) LIBERABLE RETENTION MECHANISM AND METHOD OF USE
ZA200804688B (en) Purine derivatives and methods of use thereof
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
HK1161122A1 (en) Use of 24-norudca 24-norudca
EP1946007A4 (en) ANDROSTERONE DERIVATIVES AND METHODS OF USE
IL190583A0 (en) Pth formulations and methods of use
GB0520930D0 (en) Composition and method of use
EP1906950A4 (en) ANSAMYCIN FORMULATIONS AND METHODS OF USE
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use